CMO/CDMO Biotechnology Market
CMO/CDMO Biotechnology Market Study by Standalone Services and Integrated Developments for Preclinical, Clinical, and Commercial Operation from 2024 to 2034
Analysis of CMO/CDMO Biotechnology Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
CMO/CDMO Biotechnology Market Outlook (2024 to 2034)
The global CMO/CDMO biotechnology market is estimated at US$ 67.21 billion in 2024 and is projected to reach a size of US$ 199.09 billion by 2034-end, expanding at a high-value CAGR of 11.5% between 2024 and 2034.
Companies in the biotechnology and biopharmaceutical industries hire CDMO for development and production services. Pharma/biopharma and biotechnology firms collaborate with CDMOs to delegate the development and manufacturing of pharmaceuticals. Biotechnology instruments offer a variety of services, including development, biomanufacturing, analytical testing, fill finishing, packaging, and clinical supply.
Leading CDMOs are focusing on growing their integrated capabilities from the molecule to the final product due to advancements in contract solutions. This is a noteworthy trend since it reflects the growing importance of the CMO/CDMO biotechnology market trends and faster development for biopharmaceutical and biologics developers.
To treat severe, life-threatening illnesses, leading industry participants are focusing on the creation and introduction of next-generation biotherapeutics. The pipeline for developing biologics at this time is supportive of prospects for steady growth.
Key Factors Driving Market Expansion
- Standalone services occupy a leading market share because pharmaceutical and biotechnology companies are expanding their cell-line development services.
- Prominent international CDMOs are directing their efforts toward growing their capacity for quick and flexible manufacturing.
- Asia Pacific accounts for a leading CMO/CDMO biotechnology market share and is expected to maintain its position throughout the forecast period.
| Report Attributes | Details |
|---|---|
| CMO/CDMO Biotechnology Market Size (2024E) | US$ 67.21 Billion |
| Forecasted Market Value (2034F) | US$ 199.09 Billion |
| Global Market Growth Rate (2024 to 2034) | 11.5% CAGR |
| North America Market Share (2034F) | 32.61% |
| East Asia Market Growth Rate (2024 to 2034) | 11.2% CAGR |
| Standalone Services Segment Market Share (2024E) | 59% |
| Small Molecules Segment Market Share (2024E) | 56.1% |
| Key Companies Profiled | Laboratory Corporation of America Holdings; Boehringer Ingelheim GmbH; Toyobo Co., Ltd.; Samsung Biologics; Thermo Fisher Scientific Inc.; ICON Plc. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What’s Augmenting Demand for CMO/CDMO Biotechnology Services?
“Reduction of In-House R&D Department for Companies and CRO Service Cost-effectiveness”
One of the main areas of investment in the biotech and pharmaceutical sectors is research and development. To make better pharmaceuticals at lower costs, companies invest a large portion of their capital and revenues in research and development. With price and function being the primary competitive factors in the pharmaceutical and biotechnology sectors, pharmaceutical corporations gain a notable competitive edge.
Following the rise of CRO players, many pharmaceutical companies, particularly those with modest operations, saw a reduction in their research and development departments.
As more CROs entered the market and began to provide research services at competitive prices, they overcame inside pharmaceutical R&D departments. CROs employ multiple tactics to maintain a competitive edge over leading pharmaceutical companies.
“Evolving Business Models in Biopharmaceutical CDMOs Adapting to Industry Consolidations”
The biopharmaceutical sector has seen a large number of consolidations in recent years. The primary goals of these consolidations were corporate growth and maintaining competitiveness for biopharmaceutical contract manufacturing and services.
Despite the relatively recent development of the biopharmaceutical CMO and CRO space, there has been a notable increase in demand for contract bio manufacturers. This is due to the introduction of novel therapies, new bioprocess technology, and changes in product priorities within the pharmaceutical sector. To effectively serve the demands of their stakeholders and clients, CDMOs are implementing improved business models.
How Can Market Expansion be Hindered to Some Extent?
“Stringent Legal Environment and Complexity of Contract Discussions”
Incorporation of single-use systems in manufacturing facilities facilitates the cost-effective expansion of manufacturing capacity for the CMOs. The single-use products minimize related tasks like cleaning and changeover validation while providing quick turnaround times. However, because of the legal environment and complexity of services, it is found that contract discussions between CMOs and clients are challenging.
The complexity of negotiations increases since clients and CMOs have to deal with concerns related to intellectual property rights, warranties and obligations, prices, and timetables.
“Intricacy of Biopharma Supply Chain and Operations”
The CMO and CDMO operations within the biotechnology sector are characterized by high levels of complexity in the biopharmaceutical supply chain. This complexity stems from the sensitivity of biopharmaceutical products, which require controlled temperature environments for storage and shipping. Flexibility in the supply chain is especially crucial for life-saving medications to accommodate changes in demand.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
China's CMO/CDMO biotechnology market size is influenced by backing from the government, changing regulatory environment, and growing integration with the world's biopharmaceutical supply chain.
Continuous merger and acquisition activities among American businesses are driving strong growth of the United States market. There is a growing preference for single-use bioreactors, which is helping the business expand.
Why is Demand for CMO/CDMO Biotechnology Solutions High in China?
“Government Support and Initiatives Expediting Regulatory Clearances”
| Attribute | China |
|---|---|
| Market Value (2024E) | US$ 23.93 Billion |
| Growth Rate (2024 to 2034) | 11.5% CAGR |
| Projected Value (2034F) | US$ 71.3 Billion |
The market in China has been expanding rapidly due to a combination of local and international causes. As part of a larger effort to progress in high-tech industries, the Chinese government has been actively assisting the biotech sector. Initiatives like "Made in China 2025" have given the market a boost with policies that support innovation and biotech investments, and accelerate regulatory clearances.
China's expanding aging population, rising incidence of chronic diseases, and expanding middle class, which has higher healthcare expectations, are all contributing to the country's growing need for biologic products.
Why is the United States a Profitable Market for CMO/CDMO Biotechnology Service Providers?
“Increasing Interdependency Between CMOs and SMEs”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 21.4 Billion |
| Growth Rate (2024 to 2034) | 10.3% CAGR |
| Projected Value (2034F) | US$ 56.88 Billion |
Responding to market and outsourcing demands, CMOs in the United States have expanded beyond basic manufacturing services to offer a variety of services. This expansion is propelled by steady sector growth and a rising trend of outsourcing biotechnology and pharmaceutical services by companies focusing on core competencies to enhance profit margins.
Significant portion of products authorized in the United States are manufactured by CMOs. Many small- and medium-sized enterprises (SMEs) lack the funding or capacity to establish facilities with sufficient equipment. The dominance of the United States market results from the increasing interdependency between CMOs and SMEs in the country.
Category-wise Insights
CMOs and CDMOs provide a range of standalone services to support different phases of drug development and manufacture in the biotechnology sector. The market for small-molecule drugs is sizable and is still expanding due to continuous research and development across a range of therapeutic areas.
Which Type of Service are Companies Widely Adopting?
“High Adoption of Standalone Services Enabling Companies to Focus on Core Expertise”
| Attribute | Standalone Services |
|---|---|
| Segment Value (2024E) | US$ 39.67 Billion |
| Growth Rate (2024 to 2034) | 12.2% CAGR |
| Projected Value (2034F) | US$ 125.19 Billion |
Biotechnology and biopharmaceutical firms rely on CDMOs for vital services such as biomanufacturing, analytical testing, development, clinical supply, fill-finishing, packaging, and more. Due to the growing demand for cell-line development services in the biopharmaceutical and biotechnology industries, standalone services occupy a leading market share.
For biotech and pharmaceutical businesses, particularly those without the internal resources or knowledge to handle these tasks independently, these services are essential.
Biopharmaceutical firms, especially SMEs, can outsource various aspects of their manufacturing and drug development processes with the help of these standalone services. This enables businesses to take advantage of the specific skills of CMOs and CDMOs while focusing on their main expertise, such as medication discovery and marketing.
Which Product is Projected to Occupy a Leading Market Share?
“Growing COVID-19 Vaccine Pipeline and Biologics Production Driving Need for Small Molecules”
| Attribute | Small Molecules |
|---|---|
| Segment Value (2024E) | US$ 37.71 Billion |
| Growth Rate (2024 to 2034) | 7.1% CAGR |
| Projected Value (2034F) | US$ 74.85 Billion |
The CMO/CDMO biotechnology market growth is fueled by several factors. These include the expansion of the generic drug market, the widespread adoption of small molecule drugs across various diseases, the expiration of drug patents, the demand for more advanced techniques in manufacturing active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs), increased activities such as mergers, acquisitions, and investments, the rising pipeline of COVID-19 vaccines and biologics production, and the aging population.
Small molecules play a crucial role alongside biologics. "Small molecules," which are low molecular weight substances, are significant components in medications due to their ease of cell entry and interaction with biological macromolecules like DNA and proteins. Typically, chemical synthesis is employed for their creation.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Due to the multiple vendors that contribute to market share, the pharmaceutical CDMO industry is fragmented. A direct cause of competition, especially for small-scale providers, is the presence of multiple competitors in the market, which affects service pricing. To obtain a competitive advantage, market vendors are expected to focus on providing one-stop shopping services.
- In June 2023, Catalent expanded the scope of its One Bio Suite solution to encompass various biotechnological modalities, including cellular and gene therapy, mRNA, antibody, and recombinant protein research and manufacturing.
Segmentation of CMO/CDMO Biotechnology Market Research
-
By Service:
- Standalone Services
- Integrated Developments
-
By Product:
- Large Molecules
- Small Molecules
-
By Organization:
- Small
- Mid-sized
- Large
-
By Scale of Operation:
- Preclinical
- Clinical
- Commercial
-
By Expression System:
- Mammalian
- Microbial
-
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Key Market Trends
- 4. Market Background
- 5. Market Context
- 6. Global Market - Pricing Analysis
- 7. Global Market Value Analysis 2018 to 2023 and Forecast, 2024 to 2034
- 8. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Product
- 8.1. Large Molecules
- 8.2. Small Molecules
- 9. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Service
- 9.1. Standalone Services
- 9.2. Integrated Developments
- 10. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Organization
- 10.1. Small
- 10.2. Mid-Scale of Operations
- 10.3. Large
- 11. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Scale of Operation
- 11.1. Preclinical
- 11.2. Clinical
- 11.3. Commercial
- 12. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Expression System
- 12.1. Mammalian
- 12.2. Microbial
- 13. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Region
- 13.1. North America
- 13.2. Latin America
- 13.3. Europe
- 13.4. East Asia
- 13.5. South Asia
- 13.6. Oceania
- 13.7. Middle East and Africa (MEA)
- 14. North America Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 15. Europe Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 16. Middle East and Africa Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 17. Rest of the World Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 18. Key and Emerging Countries Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 19. Market Structure Analysis
- 20. Competition Analysis
- 20.1. Laboratory Corporation of America Holdings
- 20.2. Boehringer Ingelheim GmbH
- 20.3. Toyobo Co., Ltd.
- 20.4. Samsung Biologics
- 20.5. Thermo Fisher Scientific Inc.
- 20.6. ICON Plc.
- 21. Assumptions and Acronyms Used
- 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Product
Table 02: Global Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Service
Table 03: Global Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Organization
Table 04: Global Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Scale of Operation
Table 05: Global Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Expression System
Table 06: Global Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Scale of Operation Age Group
Table 07: Global Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Region
Table 08: North America Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 09: North America Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Product
Table 10: North America Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Organization
Table 11: North America Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Service
Table 12: North America Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Scale of Operation
Table 13: North America Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Expression System
Table 14: Europe Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 15: Europe Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Product
Table 16: Europe Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Organization
Table 17: Europe Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Service
Table 18: Europe Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Scale of Operation
Table 19: Europe Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Expression System
Table 20: Middle East and Africa Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 21: Middle East and Africa Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Product
Table 22: Middle East and Africa Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Organization
Table 23: Middle East and Africa Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Service
Table 24: Middle East and Africa Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Scale of Operation
Table 25: Middle East and Africa Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Expression System
Table 26: Rest of the World Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Product
Table 27: Rest of the World Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Organization
Table 28: Rest of the World Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Service
Table 29: Rest of the World Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Scale of Operation
Table 30: Rest of the World Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Expression System
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 02: Global Market Absolute $ Opportunity, 2024 to 2034
Figure 03: Global Market Share Analysis (%), By Product, 2024 to 2034
Figure 04: Global Market Y-o-Y Analysis (%), By Product, 2024 to 2034
Figure 05: Global Market Attractiveness Analysis By Product, 2024 to 2034
Figure 06: Global Market Share Analysis (%), By Service, 2024 to 2034
Figure 07: Global Market Y-o-Y Analysis (%), By Service, 2024 to 2034
Figure 08: Global Market Attractiveness Analysis By Service, 2024 to 2034
Figure 09: Global Market Share Analysis (%), By Organization, 2024 to 2034
Figure 10: Global Market Y-o-Y Analysis (%), By Organization, 2024 to 2034
Figure 11: Global Market Attractiveness Analysis By Organization, 2024 to 2034
Figure 12: Global Market Share Analysis (%), By Scale of Operation, 2024 to 2034
Figure 13: Global Market Y-o-Y Analysis (%), By Scale of Operation, 2024 to 2034
Figure 14: Global Market Attractiveness Analysis By Scale of Operation, 2024 to 2034
Figure 15: Global Market Share Analysis (%), By Expression System, 2024 to 2034
Figure 16: Global Market Y-o-Y Analysis (%), By Expression System , 2024 to 2034
Figure 17: Global Market Attractiveness Analysis, By Expression System, 2024 to 2034
Figure 18: Global Market Share Analysis (%), By Scale of Operation Age Group, 2024 to 2034
Figure 19: Global Market Y-o-Y Analysis (%), By Scale of Operation Age Group, 2024 to 2034
Figure 20: Global Market Attractiveness Analysis By Scale of Operation Age Group, 2024 to 2034
Figure 21: Global Market Share Analysis (%), By Region, 2024 to 2034
Figure 22: Global Market Y-o-Y Analysis (%), By Region, 2024 to 2034
Figure 23: Global Market Attractiveness Analysis, By Region, 2024 to 2034
Figure 24: North America Market Value Share, By Product, 2024 (E)
Figure 25: North America Market Value Share, By Organizations 2024 (E)
Figure 26: North America Market Value Share, By Service, 2024 (E)
Figure 27: North America Market Value Share, By Scale of Operation, 2024 (E)
Figure 28: North America Market Value Share, By Expression System, 2024 (E)
Figure 29: North America Market Value Share, By Country, 2024 (E)
Figure 30: North America Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 31: North America Market Attractiveness Analysis By Product, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis By Organization, 2024 to 2034
Figure 33: North America Market Attractiveness Analysis By Service, 2024 to 2034
Figure 34: North America Market Attractiveness Analysis By Scale of Operation, 2024 to 2034
Figure 35: North America Market Attractiveness Analysis By Expression System, 2024 to 2034
Figure 36: North America Market Attractiveness Analysis By Country, 2024 to 2034
Figure 37: Europe Market Value Share, By Product, 2024 (E)
Figure 38: Europe Market Value Share, By Organizations 2024 (E)
Figure 39: Europe Market Value Share, By Service, 2024 (E)
Figure 40: Europe Market Value Share, By Scale of Operation, 2024 (E)
Figure 41: Europe Market Value Share, By Expression System, 2024 (E)
Figure 42: Europe Market Value Share, By Country, 2024 (E)
Figure 43: Europe Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 44: Europe Market Attractiveness Analysis By Product, 2024 to 2034
Figure 45: Europe Market Attractiveness Analysis By Organization, 2024 to 2034
Figure 46: Europe Market Attractiveness Analysis By Service, 2024 to 2034
Figure 47: Europe Market Attractiveness Analysis By Scale of Operation, 2024 to 2034
Figure 48: Europe Market Attractiveness Analysis By Service, 2024 to 2034
Figure 49: Europe Market Attractiveness Analysis By Country, 2024 to 2034
Figure 50: Middle East and Africa Market Value Share, By Product, 2024 (E)
Figure 51: Middle East and Africa Market Value Share, By Organization, 2024 (E)
Figure 52: Middle East and Africa Market Value Share, By Service, 2024 (E)
Figure 53: Middle East and Africa Market Value Share, By Scale of Operation, 2024 (E)
Figure 54: Middle East and Africa Market Value Share, By Expression System, 2024 (E)
Figure 55: Middle East and Africa Market Value Share, By Country, 2024 (E)
Figure 56: Middle East and Africa Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 57: Middle East and Africa Market Attractiveness Analysis By Product, 2024 to 2034
Figure 58: Middle East and Africa Market Attractiveness Analysis By Organization, 2024 to 2034
Figure 59: Middle East and Africa Market Attractiveness Analysis By Service, 2024 to 2034
Figure 60: Middle East and Africa Market Attractiveness Analysis By Scale of Operation, 2024 to 2034
Figure 61: Middle East and Africa Market Attractiveness Analysis By Expression System, 2024 to 2034
Figure 62: Middle East and Africa Market Attractiveness Analysis By Country, 2024 to 2034
Figure 63: Rest of the World Market Value Share, By Product, 2024 (E)
Figure 64: Rest of the World Market Value Share, By Organizations 2024 (E)
Figure 65: Rest of the World Market Value Share, By Service, 2024 (E)
Figure 66: Rest of the World Market Value Share, By Scale of Operation, 2024 (E)
Figure 67: Rest of the World Market Value Share, By Expression System, 2024 (E)
Figure 68: Rest of the World Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 69: Rest of the World Market Attractiveness Analysis By Product, 2024 to 2034
Figure 70: Rest of the World Market Attractiveness Analysis By Organization, 2024 to 2034
Figure 71: Rest of the World Market Attractiveness Analysis By Service, 2024 to 2034
Figure 72: Rest of the World Market Attractiveness Analysis By Scale of Operation, 2024 to 2034
Figure 73: Rest of the World Market Attractiveness Analysis By Expression System, 2024 to 2034
Figure 74: United States Market Value Share, By Product, 2024 to 2034
Figure 75: United States Market Value Share, By Organization, 2024 to 2034
Figure 76: United States Market Value Share, By Service, 2024 to 2034
Figure 77: United States Market Value Share, By Scale of Operation Age Group, 2024 to 2034
Figure 78: United States Market Value Share, By Expression System, 2024 to 2034
Figure 79: United States Market Value Analysis (US$ Mn), 2024 to 2034
Figure 80: Canada Market Value Share, By Product, 2024 to 2034
Figure 81: Canada Market Value Share, By Organization, 2024 to 2034
Figure 82: Canada Market Value Share, By Service, 2024 to 2034
Figure 83: Canada Market Value Share, By Scale of Operation Age Group, 2024 to 2034
Figure 84: Canada Market Value Share, By Expression System, 2024 to 2034
Figure 85: Canada Market Value Analysis (US$ Mn), 2024 to 2034
Figure 86: United Kingdom Market Value Share, By Product, 2024 to 2034
Figure 87: United Kingdom Market Value Share, By Organization, 2024 to 2034
Figure 88: United Kingdom Market Value Share, By Service, 2024 to 2034
Figure 89: United Kingdom Market Value Share, By Scale of Operation Age Group, 2024 to 2034
Figure 90: United Kingdom Market Value Share, By Expression System, 2024 to 2034
Figure 91: United Kingdom Market Value Analysis (US$ Mn), 2024 to 2034
Figure 92: Germany Market Value Share, By Product, 2024 to 2034
Figure 93: Germany Market Value Share, By Organization, 2024 to 2034
Figure 94: Germany Market Value Share, By Service, 2024 to 2034
Figure 95: Germany Market Value Share, By Scale of Operation Age Group, 2024 to 2034
Figure 96: Germany Market Value Share, By Expression System, 2024 to 2034
Figure 97: Germany Market Value Analysis (US$ Mn), 2024 to 2034
Figure 98: France Market Value Share, By Product, 2024 to 2034
Figure 99: France Market Value Share, By Organization, 2024 to 2034
Figure 100: France Market Value Share, By Service, 2024 to 2034
Figure 101: France. Market Value Share, By Scale of Operation Age Group, 2024 to 2034
Figure 102: France Market Value Share, By Expression System, 2024 to 2034
Figure 103: France Market Value Analysis (US$ Mn), 2024 to 2034
Figure 104: Italy Market Value Share, By Product, 2024 to 2034
Figure 105: Italy Market Value Share, By Organization, 2024 to 2034
Figure 106: Italy Market Value Share, By Service, 2024 to 2034
Figure 107: Italy Market Value Share, By Scale of Operation Age Group, 2024 to 2034
Figure 108: Italy Market Value Share, By Expression System, 2024 to 2034
Figure 109: Italy Market Value Analysis (US$ Mn), 2024 to 2034
Figure 110: Spain Market Value Share, By Product, 2024 to 2034
Figure 111: Spain Market Value Share, By Organization, 2024 to 2034
Figure 112: Spain Market Value Share, By Service, 2024 to 2034
Figure 113: Spain Market Value Share, By Scale of Operation Age Group, 2024 to 2034
Figure 114: Spain Market Value Share, By Expression System, 2024 to 2034
Figure 115: Spain Market Value Analysis (US$ Mn), 2024 to 2034
Figure 116: GCC Countries. Market Value Share, By Product, 2024 to 2034
Figure 117: GCC Countries Market Value Share, By Organization, 2024 to 2034
Figure 118: GCC Countries Market Value Share, By Service, 2024 to 2034
Figure 119: GCC Countries Market Value Share, By Scale of Operation, 2024 to 2034
Figure 120: GCC Countries Market Value Share, By Expression System, 2024 to 2034
Figure 121: GCC Countries Market Value Analysis (US$ Mn), 2024 to 2034
Figure 122: South Africa Market Value Share, By Product, 2024 to 2034
Figure 123: South Africa Market Value Share, By Organization, 2024 to 2034
Figure 124: South Africa Market Value Share, By Service, 2024 to 2034
Figure 125: South Africa Market Value Share, By Scale of Operation Age Group, 2024 to 2034
Figure 126: South Africa Market Value Share, By Expression System, 2024 to 2034
Figure 127: South Africa Market Value Analysis (US$ Mn), 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How much is the CMO/CDMO biotechnology market worth in 2024?
The global CMO/CDMO biotechnology market is estimated at US$ 67.21 billion in 2024.
What is the sales forecast for CMO/CDMO biotechnology solutions for 2034?
By 2034-end, worldwide sales of CMO/CDMO biotechnology solutions are forecasted to reach US$ 199.09 billion.
At what rate is the demand for CMO/CDMO biotechnology solutions projected to rise?
Demand for CMO/CDMO biotechnology solutions is forecasted to rise at 11.5% CAGR over the next 10 years.
How are sales of CMO/CDMO biotechnology solutions evolving in East Asia?
The market in East Asia is projected to advance at 11.2% CAGR from 2024 to 2034.
Which scale of operation segment is projected to expand significantly?
The commercial segment is forecasted to advance at a CAGR of 11.7% from 2024 to 2034.
CMO/CDMO Biotechnology Market